Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1671 1672
This examiner grants 66% of resolved cases
Stacy Brown Chen, an examiner in Tech Center 1600 and Art Unit 1648, has 940 resolved cases. The allowance rate is 66.1%, which represents a solid majority of cases. The median days to allowance is 1135, reflecting a standard timeline for successful prosecution. This 1135-day duration is a key metric for planning in Art Unit 1648. The 66.1% rate indicates a balanced examination environment.
The interview lift is 40.6%, which is quite high. This indicates that interviews are very effective at moving cases toward allowance, especially when compared to the 66.1% baseline. In Tech Center 1600, the 1135-day median pendency can be managed more successfully with direct communication. The 40.6% lift is a critical tool for practitioners seeking to improve their odds. With 940 resolved cases, these metrics provide a clear guide for strategy.
Applicants should use the 40.6% interview lift to their advantage to overcome the 66.1% baseline. The 1135-day median to allowance should be factored into any long-term prosecution plan. Overall, the 940 cases suggest that direct engagement is a key strategy for success with this examiner. Practitioners in Art Unit 1648 should prioritize interviews to move beyond the initial 66.1% allowance probability.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18549134 | COMPOSITIONS, KITS, AND METHODS FOR VARIANT-RESISTANT DETECTION OF TARGET VIRAL SEQUENCES | Non-Final OA | LIFE TECHNOLOGIES CORPORATION |
| 18272512 | VARIANT STRAIN-BASED CORONAVIRUS VACCINES | Non-Final OA | ModernaTX, Inc. |
| 18691351 | COMPOSITIONS, KITS, AND METHODS FOR DUPLEX IMMUNOASSAY FOR ANTI-SARS-COV-2 ANTIBODIES | Non-Final OA | Siemens Healthcare Diagnostics Inc. |
| 18360190 | Glycoengineered protein nanoparticles and uses thereof | Non-Final OA | University of Washington |
| 18558830 | Compositions and Methods for Detecting Hepatitis Delta Virus by a Dual-Target Assay | Non-Final OA | Roche Molecular Systems, Inc. |
| 18347698 | SELF-AMPLIFYING RNA ENCODING AN INFLUENZA VIRUS ANTIGEN | Final Rejection | PFIZER INC. |
| 18276905 | INFLUENZA VACCINE COMPOSITIONS AND METHODS OF USING SAME | Final Rejection | Children's Hospital Medical Center |
| 18281540 | POLYSACCHARIDE ADJUVANTS FOR VIRUS VACCINES | Non-Final OA | Children's Medical Center Corporation |
| 18034720 | GENE SHUFFLED LYSSAVIRUS VACCINE | Final Rejection | Thomas Jefferson University |
| 18715638 | CAPILLARY ELECTROPHORESIS METHODS FOR CHARACTERIZING GENOME INTEGRITY | Non-Final OA | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. |
| 18551547 | COMPOSITIONS AND METHODS FOR RAPID COVID-19 DETECTION | Non-Final OA | DUKE UNIVERSITY |
| 17838114 | DURABLE VACCINATION | Final Rejection | Gritstone bio, Inc. |
| 18032530 | RECOMBINANT CLASSICAL SWINE FEVER VIRUS E2 PROTEIN | Final Rejection | Boehringer Ingelheim Vetmedica (China) Co., Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy